Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Follow-Up Questions
Qui est le CEO de Protara Therapeutics Inc ?
Mr. Jesse Shefferman est le President de Protara Therapeutics Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action TARA ?
Le prix actuel de TARA est de $5.5, il a increased de 0.2% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Protara Therapeutics Inc ?
Protara Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Protara Therapeutics Inc ?
La capitalisation boursière actuelle de Protara Therapeutics Inc est de $212.2M
Est-ce que Protara Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Protara Therapeutics Inc, y compris 3 achat fort, 8 achat, 1 maintien, 0 vente et 3 vente forte
